2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1078

Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1459

Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1563

Enhanced Expression of mRNA for Response Gene to Complement 32 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1137

Enhancing Pediatric Rheumatology Education through Computer-Assisted Fellow-Taught Case Modules

Education - Poster

9:00AM-11:00AM: Abstract Number: 1305

Enriching Rheumatoid Arthritis Trial Cohorts with Erosion Progressors By Screening for Active Erosions (Erosions with Osteitis) with MRI

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1221

Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1814

Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1884

Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1244

Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1413

Establishing Clinical Severity for Patient Reported Outcomes Measurement Information System Measures in Adult Patients with Rheumatic Diseases

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1431

Estimates of Global Status By Physicians and Patients Are More Likely to be Discordant in Osteoarthritis Than in Rheumatoid Arthritis

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1288

Evaluating Rheumatoid Arthritis Disease Activity Using Global Assessment of 18f-FDG Uptake in the Joints

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1253

Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1948

Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1600

Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib By RAPID3: An Analysis of Data from 6 Phase 3 Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].